Basma Radwan Ibrahim's questions to Amylyx Pharmaceuticals Inc (AMLX) leadership • Q3 2024
Question
Basma Radwan Ibrahim of Leerink Partners, on for Marc Goodman, asked if the ORION study in PSP will use tau PET imaging in addition to CSF biomarkers for its decision-making. She also questioned if the Phase III avexitide trial will include an active standard-of-care comparator arm.
Answer
Dr. Camille Bedrosian, Chief Medical Officer, responded that the PSP study will primarily look at CSF biomarkers compared to baseline, referencing the strong signal seen in the prior Alzheimer's study. For the avexitide trial, she explained that since there are no approved therapies for PBH, the trial will be placebo-controlled, with all participants continuing their medical nutrition therapy.